Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyCommunity-Care IV ustekinumab Prior Auth Coverage …
    Ask Trek AI about this page
    CurrentCommunity-CarePolicy N/A

    Intravenous ustekinumab (all brands) — Medical Benefit Medication Utilization Policy

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This medical benefit medication utilization policy governs prior authorization and coverage criteria for intravenous ustekinumab products (originator and biosimilars) for Crohn's disease and ulcerative colitis for Community-Care members.

    Policy Summary
    PayerCommunity-Care
    PolicyIntravenous ustekinumab (all brands) — Medical Benefit Medication Utilization Policy
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewMar 1, 2025
    Next Review DateMar 1, 2025
    Key ActionObtain prior authorization from a gastroenterology specialist with diagnosis, patient weight, requested vial quantity, and confirmation the patient is not currently established on ustekinumab.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2approved indications

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3
    dose tiers
    single doseauthorization period
    HCPCS+Qbilling codes
    Selarsdipreferred product

    Coverage Criteria for Intravenous Ustekinumab

    Initial Therapy - Crohn's disease

    Covered when ALL of the following are met for Crohn's disease:

    Crohn's initial IV dose criteria: Prescribed by a gastroenterology specialist.
    Crohn's initial IV dose criteria: Diagnosis of moderately to severely active Crohn's disease.

    Crohn's initial IV dose criteria

    • Dose options: 260 mg (2 of the 130 mg vials) — weight ≤ 55 kg and weight provided.
    • Dose options: 390 mg (3 of the 130 mg vials) — weight > 55 kg and ≤ 85 kg and weight provided.
    • Dose options: 520 mg (4 of the 130 mg vials) — weight > 85 kg and weight provided.
    Crohn's initial IV dose criteria: Patient is not currently established on ustekinumab.

    Initial Therapy - Ulcerative colitis

    Covered when ALL of the following are met for Ulcerative Colitis:

    Ulcerative colitis initial IV dose criteria: Prescribed by a gastroenterology specialist.
    Ulcerative colitis initial IV dose criteria: Diagnosis of moderately to severely active ulcerative colitis.

    Ulcerative colitis initial IV dose criteria

    • Dose options: 260 mg (2 of the 130 mg vials) — weight ≤ 55 kg and weight provided.
    • Dose options: 390 mg (3 of the 130 mg vials) — weight > 55 kg and ≤ 85 kg and weight provided.

    Authorization is limited to a single intravenous (IV) induction dose of ustekinumab for Crohn's disease or ulcerative colitis. This policy does not address ongoing or maintenance dosing—requests for repeat or maintenance infusions should not be submitted under this authorization and will require separate review or a different policy pathway. If approved, the single authorized dose must be dispensed within 1 month of approval.

    Billing and Coding

    Applicable HCPCS / Q-code Billing CodesHCPCS
    J3358Ustekinumab, for intravenous injection, 1 mg.
    Q5098Injection, ustekinumab-srlf (imuldosa), biosimilar, 1 mg.
    Q5099Injection, ustekinumab-stba (steqeyma), biosimilar, 1 mg.
    Q5100Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg.
    Q5138Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg.
    Q9997Injection, ustekinumab-ttwe (pyzchiva), intravenous, 1 mg.
    Q9998Injection, ustekinumab-aekn (selarsdi), biosimilar, 1 mg.
    Q9999Injection, ustekinumab-aauz (otulfi), biosimilar, 1 mg.
    inv-05: Weight-based vial quantity
    ≤55 kg2 vials (260 mg)
    >55–85 kg3 vials (390 mg)
    >85 kg4 vials (520 mg)

    Provider Actions and Requirements

    Prior Authorization

    Prior authorization required for initial IV ustekinumab

    Prior authorization is required for the initial intravenous ustekinumab induction dose. The request must be submitted by a gastroenterology specialist and include the diagnosis, patient weight, the requested dose expressed as the appropriate vial quantity (2, 3, or 4 vials per weight-based dosing), and confirmation that the patient is not currently established on ustekinumab.

    • Requested dose must match weight-based dosing: 2 vials (≤55 kg), 3 vials (>55–85 kg), 4 vials (>85 kg).
    • Authorization is for a single IV induction dose (single fill within 1 month if approved).
    Step Therapy

    Step therapy: preferred product (Selarsdi IV) required first

    The policy requires use of the preferred product (Selarsdi IV) first; other IV ustekinumab products will be considered only if the patient has a contraindication, intolerance, or has tried and failed the preferred product.

    • Provider must document reason (contraindication, intolerance, or treatment failure) to request a non-preferred IV ustekinumab product.

    Background

    Ustekinumab IV is indicated for use in patients with moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis. The initial IV induction dose is weight-based and must match one of the specified vial quantities: 260 mg (2 x 130 mg vials) for patients ≤55 kg, 390 mg (3 vials) for patients >55–85 kg, or 520 mg (4 vials) for patients >85 kg. Initial IV dosing must be prescribed by a gastroenterology specialist and is intended for patients who are not currently established on ustekinumab.

    Definitions

    inv-11: Not currently established
    DefinitionNot currently established on ustekinumab
    Context for initial IV doseProvider must confirm the patient is not currently established on ustekinumab when requesting the initial IV induction dose.
    Documentation requirementPatient weight and requested vial quantity must be provided to confirm appropriate induction dose.
    Policy Summary
    PayerCommunity-Care
    PolicyIntravenous ustekinumab (all brands) — Medical Benefit Medication Utilization Policy
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewMar 1, 2025
    Next Review DateMar 1, 2025
    Key ActionObtain prior authorization from a gastroenterology specialist with diagnosis, patient weight, requested vial quantity, and confirmation the patient is not currently established on ustekinumab.
    SourceLink
    On This Page
    Coverage Criteria for Intravenous UstekinumabBilling and CodingProvider Actions and RequirementsBackgroundDefinitions
    Dose options: 520 mg (4 of the 130 mg vials) — weight > 85 kg and weight provided.
    Ulcerative colitis initial IV dose criteria: Patient is not currently established on ustekinumab.
    Documentation Required

    Document gastroenterology specialty, diagnosis, weight, and not currently established

    When requesting the initial IV dose, the provider must document that the prescriber is a gastroenterology specialist, specify the diagnosis (moderately to severely active Crohn's disease or ulcerative colitis), provide the patients weight, and confirm the patient is not currently established on ustekinumab.

    • Include requested vial quantity corresponding to weight-based dosing (2 vials for ≤55 kg; 3 vials for >55–85 kg; 4 vials for >85 kg).
    • Authorization is for a single IV induction dose only.
    Denial Risk

    Denial risk for non-preferred ustekinumab IV products

    Requests for non-preferred intravenous ustekinumab products may be denied if the patient has not demonstrated a contraindication, intolerance, or treatment failure with the preferred product (Selarsdi IV).

    • Ensure documentation of contraindication, intolerance, or prior treatment failure with Selarsdi IV to avoid denial.